Search Results - "Pinter, Tamás"

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES) by Pinter, Tamás, Klippel, Zandra, Cesas, Alvydas, Croitoru, Adina, Decaestecker, Jochen, Gibbs, Peter, Hotko, Yevhen, Jassem, Jacek, Kurteva, Galina, Novotny, Jan, O'Reilly, Seamus, Salek, Tomas, Reiner, Maureen, Morrow, Phuong Khanh, Choi, Mi Rim, Whittaker, Sadie, Blanke, Charles

“…In a phase III, double-blind trial, 845 patients with advanced colorectal cancer receiving bevacizumab plus first-line chemotherapy (FOLFOX [leucovorin),…”
Get full text

Adjuvant Trastuzumab in HER2-Positive Breast Cancer by Slamon, Dennis, Eiermann, Wolfgang, Robert, Nicholas, Pienkowski, Tadeusz, Martin, Miguel, Press, Michael, Mackey, John, Glaspy, John, Chan, Arlene, Pawlicki, Marek, Pinter, Tamas, Valero, Vicente, Liu, Mei-Ching, Sauter, Guido, von Minckwitz, Gunter, Visco, Frances, Bee, Valerie, Buyse, Marc, Bendahmane, Belguendouz, Tabah-Fisch, Isabelle, Lindsay, Mary-Ann, Riva, Alessandro, Crown, John

“…Trastuzumab added to a nonanthracycline regimen to treat HER2-positive breast cancer resulted in rates of disease-free and overall survival that were similar…”
Get full text

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer by Van Cutsem, Eric, Köhne, Claus-Henning, Hitre, Erika, Zaluski, Jerzy, Chang Chien, Chung-Rong, Makhson, Anatoly, D'Haens, Geert, Pintér, Tamás, Lim, Robert, Bodoky, György, Roh, Jae Kyung, Folprecht, Gunnar, Ruff, Paul, Stroh, Christopher, Tejpar, Sabine, Schlichting, Michael, Nippgen, Johannes, Rougier, Philippe

“…Previous trials have shown that the combination of fluorouracil-based chemotherapy and cetuximab is active when used as salvage treatment in patients with…”
Get full text

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) by Finn, Richard S., Boer, Katalin, Bondarenko, Igor, Patel, Ravindranath, Pinter, Tamas, Schmidt, Marcus, Shparyk, Yaroslav V., Thummala, Anu, Voitko, Nataliia, Bananis, Eustratios, McRoy, Lynn, Wilner, Keith, Huang, Xin, Kim, Sindy, Slamon, Dennis J., Ettl, Johannes

“…Purpose Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, approved in combination with endocrine therapy for the treatment of women and men with…”
Get full text

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) by HOFF, Paulo M, HOCHHAUS, Andreas, EYLL, Brigitte Van, PIKE, Laura, FIELDING, Anitra, ROBERTSON, Jane D, SAUNDERS, Mark P, PESTALOZZI, Bernhard C, TEBBUTT, Niall C, JIN LI, TAE WON KIM, KOYNOV, Krassimir D, KURTEVA, Galina, PINTER, Tamás, YING CHENG

“…Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signaling with activity against all three VEGF receptors. HORIZON II…”
Get full text

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study by Finn, Richard S, MD, Crown, John P, Prof, Lang, Istvan, MD, Boer, Katalin, MD, Bondarenko, Igor M, Prof, Kulyk, Sergey O, MD, Ettl, Johannes, MD, Patel, Ravindranath, MD, Pinter, Tamas, MD, Schmidt, Marcus, MD, Shparyk, Yaroslav, MD, Thummala, Anu R, MD, Voytko, Nataliya L, MD, Fowst, Camilla, MD, Huang, Xin, PhD, Kim, Sindy T, BS, Randolph, Sophia, MD, Slamon, Dennis J, Prof

“…Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of…”
Get full text

Pre-treatment PET/MRI based FDG and DWI imaging parameters for predicting HPV status and tumor response to chemoradiotherapy in primary oropharyngeal squamous cell carcinoma (OPSCC) by Freihat, Omar, Tóth, Zoltán, Pintér, Tamás, Kedves, András, Sipos, Dávid, Cselik, Zsolt, Lippai, Norbert, Repa, Imre, Kovács, Árpád

“…•ADC might be able to predict HPV as a non-invasive technique.•No correlation between FDG imaging parameters and HPV status.•Metabolic tumor imaging parameters…”
Get full text

Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study by SMITH, Robert E, AAPRO, Matti S, LUDWIG, Heinz, PINTER, Tamds, SMAKAL, Martin, CIULEANU, Tudor E, LI CHEN, LILLIE, Tom, GLASPY, John A

“…Purpose The efficacy and safety of darbepoetin alfa (DA) for treating patients with active cancer and anemia not receiving or planning to receive cytotoxic…”
Get full text

Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences by Tóth, Erika, Kürönya, Zsófia, Soós, Edina, Pintér, Tamás, Butz, Henriett, Horváth, Zsolt, Csernák, Erzsébet, Grolmusz, Vince Kornél, Székely, Judit, Straussz, Tamás, Lövey, József, Jánvári, Levenete, Báthory-Fülöp, László, Nagy, Péter, Polgár, Csaba, Patócs, Attila

“…Recent developments in molecular genetic testing methods (e.g. next-generation sequencing [NGS]-panels) largely accelerated the process of finding the most…”
Get full text

Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia by BASTIT, Laurent, VANDEBROEK, An, ALTINTAS, Sevilay, GAEDE, Bernd, PINTER, Tamds, SUTO, Tamas S, MOSSMAN, Tony W, SMITH, Kay E, VANSTEENKISTE, Johan F

“…Purpose The concomitant use of intravenous (IV) iron as a supplement to erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia is…”
Get full text

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study by Freyer, Gilles, Martinez-Jañez, Noelia, Kukielka-Budny, Bożena, Ulanska, Malgorzata, Bourgeois, Hugues, Muñoz, Montserrat, Morales, Serafin, Calero, Juan Bayo, Cortesi, Laura, Pintér, Tamás, Palácová, Markéta, Cherciu, Nelli, Petru, Edgar, Ettl, Johannes, de Almeida, Cécilia, Villanova, Gustavo, Raymond, Romain, Minh, Christine Ta Thanh, Rodrigues, Ana, Cazzaniga, Marina E.

“…Single-agent oral vinorelbine is a standard of care for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast…”
Get full text

Get reliable laboratory findings - how to recognize the deceptive effects of angiotensin-converting enzyme inhibitor therapy in the laboratory diagnostics of sarcoidosis? by Szabó, Attila Ádám, Enyedi, Enikő Edit, Altorjay, István Tibor, Hajnal, Péter, Pintér, Tamás Bence, Mányiné, Ivetta Siket, Váradi, Csongor, Bányai, Emese, Tóth, Attila, Papp, Zoltán, Fagyas, Miklós

“…Serum angiotensin-converting enzyme (ACE) is the only biomarker routinely used in the laboratory diagnostics of sarcoidosis, and ACE inhibitor (ACEi) drugs are…”
Get more information

Time-dependent leakage model for the identification of defective fuel assemblies of VVER-type nuclear reactors. Part 2: Expediting the solution and applications to a nuclear power plant by Kristóf Szarvas, Csongor, Radócz, Gábor, Gerényi, Anita, Szabados, György, Pintér, Tamás, Rozmanitz, Péter, Kirchknopf, Péter, Szalóki, Imre

Get full text

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial by Mackey, John R, Prof, Martin, Miguel, Prof, Pienkowski, Tadeusz, Prof, Rolski, Janusz, MD, Guastalla, Jean-Paul, MD, Sami, Amer, MD, Glaspy, John, MD, Juhos, Eva, MD, Wardley, Andrew, MD, Fornander, Tommy, MD, Hainsworth, John, MD, Coleman, Robert, MD, Modiano, Manuel R, MD, Vinholes, Jeferson, MD, Pinter, Tamas, MD, Rodríguez-Lescure, Álvaro, MD, Colwell, Bruce, MD, Whitlock, Pierre, MD, Provencher, Louise, MD, Laing, Kara, MD, Walde, David, MD, Price, Chris, MD, Hugh, Judith C, MD, Childs, Barrett H, MD, Bassi, Kimberly, BS, Lindsay, Mary-Ann, PharmD, Wilson, Véronique, MSc, Rupin, Matthieu, MSc, Houé, Vincent, MSc, Vogel, Charles, MD

“…Summary Background We compared standard adjuvant anthracycline chemotherapy with anthracycline–taxane combination chemotherapy in women with operable…”
Get full text

Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study by SABBATINI, Paul, HARTER, Philipp, BIDZINSKI, Mariusz, CASADO, Antonio, MARTONI, Andrea, COLOMBO, Nicoletta, HOLLOWAY, Robert W, SELVAGGI, Luigi, LI, Andrew, DEL CAMPO, Jose, CWIERTKA, Karel, PINTER, Tamas, SCAMBIA, Giovanni, VERMORKEN, Jan B, PUJADE-LAURAINE, Eric, SCARTONI, Simona, BERTOLOTTI, Monica, SIMONELLI, Cecilia, CAPRIATI, Angela, MAGGI, Carlo Alberto, BEREK, Jonathan S, PFISTERER, Jacobus, SEHOULI, Jalid, MEIER, Werner, WIMBERGER, Pauline, BAUMANN, Klaus H, KURZEDER, Christian, SCHMALFELDT, Barbara, CIBULA, David

“…To determine whether abagovomab maintenance therapy prolongs recurrence-free (RFS) and overall survival (OS) in patients with ovarian cancer in first clinical…”
Get full text

Diffusion-Weighted Imaging (DWI) derived from PET/MRI for lymph node assessment in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) by Freihat, Omar, Pinter, Tamas, Kedves, András, Sipos, Dávid, Cselik, Zsolt, Repa, Imre, Kovács, Árpád

“…To determine the usefulness of Diffusion Weighted Imaging (DWI) derived from PET/MRI in discriminating normal from metastatic lymph nodes and the correlation…”
Get full text

Effects of Foliar Biofertilizer Sprays on Nutrient Uptake, Yield, and Quality Parameters of Blaufrankish (Vitis vinifera L.) Grapes by Nagy, Péter Tamás, Pintér, Tamás

“…Nowadays the main task of scientists is to find natural ways of improving plant productivity that lead to environmentally friendly agriculture. Biofertilizers…”
Get full text

Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial by NABHOLTZ, Jean-Marc, FALKSON, Carla, VOROBIOF, Daniel, LEONARD, Robert, KENNEDY, Ian, AZLI, Nacer, MURAWSKY, Michael, RIVA, Alessandro, POUILLART, Pierre, CAMPOS, Daniel, SZANTO, Janos, MARTIN, Miguel, CHAN, Stephen, PIENKOWSKI, Tadeuz, ZALUSKI, Jerzy, PINTER, Tamas, KRZAKOWSKI, Maciej

“…This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT) with doxorubicin and cyclophosphamide (AC) as first-line chemotherapy…”
Get full text

Activities of 134Cs, 135Cs and 137Cs in the primary coolant of VVER-440 reactors by Nagy, Péter, Vajda, Nóra, Pintér, Tamás, Fél, Kornél

“…Activities of 134 Cs, 137 Cs and 135 Cs were determined in primary coolant samples of VVER-440 reactors. 135 Cs was measured by inductively coupled plasma mass…”
Get full text

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study by Martin, Miguel, Prof, Roche, Henri, Prof, Pinter, Tamas, MD, Crown, John, Prof, Kennedy, M John, MB, Provencher, Louise, MD, Priou, Frank, MD, Eiermann, Wolfgang, Prof, Adrover, Encarna, MD, Lang, Istvan, Prof, Ramos, Manuel, MD, Latreille, Jean, FRCPC, Jagiełło-Gruszfeld, Agnieszka, MD, Pienkowski, Tadeusz, MD, Alba, Emilio, MD, Snyder, Raymond, MMed, Almel, Sachin, MD, Rolski, Janusz, MD, Munoz, Montserrat, MD, Moroose, Rebecca, MD, Hurvitz, Sara, MD, Baños, Ana, BSc, Adewoye, Henry, MD, Hei, Yong-Jiang, MD, Lindsay, Mary-Ann, PhD, Rupin, Matthieu, MSc, Cabaribere, David, MSc, Lemmerick, Yasmin, MBA, Mackey, John R, Prof

“…Summary Background Vascular endothelial growth factor (VEGF) has a crucial role in angiogenesis, and is a valid target in metastatic breast cancer. Motesanib…”
Get full text